Top Markets
Coin of the day
Chinook Therapeutics, Inc. Chinook Therapeutics, Inc.

Chinook Therapeutics, Inc.

KDNY
Rang in aandelen #7141
Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical... Chinook Therapeutics, Inc., a biotechnology enterprise in the clinical development phase, is dedicated to the identification, progression, and market introduction of precise medical treatments for kidney-related conditions. The company's primary therapeutic candidate, atrasentan, is an endothelin receptor antagonist currently in Phase III clinical trials. This drug aims to treat IgA nephropathy and various other glomerular diseases characterized by proteinuria. Beyond its lead program, Chinook's investigational pipeline includes BION-1301, an anti-APRIL monoclonal antibody, which is presently being evaluated in a Phase I/II study for IgA nephropathy. Another promising candidate is CHK-336, an oral small molecule designed to inhibit LDHA, intended for patients with primary hyperoxaluria. The firm also maintains active research initiatives exploring solutions for other uncommon and severe chronic kidney ailments. Chinook Therapeutics, Inc. is based in Seattle, Washington.
Aandeelprijs
$40.39
Laatst gesynchroniseerd: 2023-08-18
Marktkapitalisatie
$1.70B
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
US
Handel Chinook Therapeutics, Inc. (KDNY)

Categorie

Koersgeschiedenis voor Chinook Therapeutics, Inc. (KDNY)
Hoogste slotkoers: $40.34 op 2023-08-01

Laagste slotkoers: $177.63 op 2015-04-01
Koersgeschiedenis van Chinook Therapeutics, Inc. van 2015 tot 2026
Jaarlijkse koersprestatie
Jaar Prestaties
2023 63.66%
2022 55.54%
2021 0.37%
2020 175.05%
2019 -57.15%
2018 -67.16%
2017 -26.51%
2016 -62.61%
2015 0.00%
Aandelenkoers van vergelijkbare bedrijven of concurrenten
Bedrijf Aandelenkoers Verandering 1jr% Land
$548.36 39.87%
US
$1.06K 50.29%
NL
$121.14 -12.77%
AU
$140.81 475.44%
US
$765.25 7.74%
CH